XRYMD, did you notice the no. of patients with SD[Stable disease]in Table 3? It was 20, or 53%. We may hear more about those in late March. And this is an IST conducted trial by Dr. Yopp as chief investigator. Dr. Yopp has a disclosure he is a consultant to Bayer, who has approval, I believe, for use of Nexavar[sorafenib] in Japan, with a heavy HCC population.
Market Data 
Markets 
AI
